英夫利昔治疗难治性儿童克罗恩病1例及文献复习

Infliximab in the treatment of refractory children with Crohn’s disease: a case report and literature review

目的探讨生物制剂治疗难治性儿童克罗恩病的长期疗效与安全性。方法回顾性分析我院1例长期使用英夫利昔治疗的难治性儿童克罗恩病患者的临床资料,并进行相关文献复习。结果患者在初始使用英夫利昔后获得了免疫应答,维持治疗过程中,在持续缓解2年后出现了复发,重新使用英夫利昔治疗后再次获得免疫应答。结论临床工作中应根据儿童克罗恩病患者年龄、生长情况、病情持续时间、有无肠外并发症等为每位患者设定个性化、合理有效的生物治疗方案,对患者意义重大。

Objective To explore the long-term efficacy and safety of biological agents in the treatment of refractory children with Crohn’s disease.Methods Retrospective analysis of clinical data of a patient with refractory Crohn’s disease who was treated with infliximab for a long time.And the associated literatures were reviewd.Results The patient had a primary response after infliximab treatment,during the maintenance treatment,recurrence occurred after 2 years of sustained remission,and recaptured response after re-use infliximab.Conclusion In clinical work,a personalized,reasonable and effective biological treatment plan should be set for each pediatric crohn’s disease according to the age,growth,duration of the disease,and the presence or absence of extraintestinal complications,which is great significance to the patient.